These 10 Firms Are On Fire Today

6. ImmunityBio, Inc. (NASDAQ:IBRX)

ImmunityBio rallied by 7.23 percent on Thursday to end at $2.67 apiece following a strong earnings performance and ratings upgrade from investment companies.

In its earnings release, ImmunityBio, Inc. (NASDAQ:IBRX) said it narrowed its net loss attributable to stockholders by 3.3 percent to $129.6 million from the $134.1 million registered in the same period last year, as revenues skyrocketed by 41,192 percent to $16.5 million from only $40,000 in the same period last year.

The higher revenues were driven by the strong performance of its Anktiva, an immunotherapy treatment for non-muscle invasive bladder cancer (NMIBC). According to the company, it continues to experience steady growth as urologists increase their use of the said treatment.

Following the results, two investment firms gave a “buy” recommendation on its stock.

It also earned an $8 price target from HC Wainwright and a $6 price target from BTIG.